Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
doi: 10.1155/2018/1729653
Join Vumedi Select specialty Your main specialty Adult & Family Medicine Allergy, Asthma, Immunology Anesthesiology Cardiology Dental Dermatology Emergency Medicine Endocrinology Gastroenterology & Hepatology General Surgery Hematology & Oncology Infectious Disease Medical Genetics Nephrology Neurology Neurosurgery Obstetrics/Gynecology Ophthalmology Oral Maxillofacial Orthopaedics Otolaryngology Pathology Pediatrics Physical Medicine & Rehab Plastic Surgery Podiatry Preventive Medicine Psychiatry Pulmonology Radiation Oncology Radiology Rheumatology Urology First name Last name Email Choose Password Topics in this Video
Future GLP-1 trends: new drugs and therapies on the horizon The future of weight management may soon involve more than current GLP-1s: Amylin mimetics: These compounds mimic another satiety hormone and may complement GLP-1s. Mazdutide: A dual glucagon/GLP-1 agonist showing strong Phase 3 results and promising greater weight loss. Oral GLP-1s: Pills in development could improve convenience. Muscle-preserving combinations: Researchers are exploring co-therapies to prevent loss of lean mass during weight loss. Providers should prepare for a rapidly evolving landscape and educate patients about upcoming options. Key takeaways on GLP-1 trends for providers and patients Efficacy varies across drugs and doses
236,237 Insulin not only directly lowers blood glucose levels but also further inhibits glucagon secretion from -cells through a feedback mechanism
Patients who stop these medications should work closely with their healthcare provider to monitor weight, blood glucose, and other metabolic parameters
